Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Overview:

ADCs and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In NSCLC, several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In SCLC, novel bispecific T-cell engagers and ADCs are driving meaningful advances in a historically limited therapeutic landscape. As these drug classes expand across lines of therapy, clinicians face growing complexity in treatment selection, sequencing, toxicity management, and biomarker-driven decision-making.

The Medical Crossfire format is uniquely suited to closing these gaps, bringing together leading thoracic oncology experts at the point where practice-changing data emerges. Its structured debate format allows expert disagreement to surface — and be resolved — in real time, giving physicians greater confidence to implement these cutting-edge therapies in their practice.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Identify the molecular targets and mechanisms of action of individual ADCs and bispecific antibodies relevant to the treatment of NSCLC and SCLC
• Evaluate clinical trial data for approved and investigational ADCs and bispecifics in lung cancer
• Develop individualized treatment strategies for patients with lung cancer, incorporating ADCs and bispecifics, accounting for patient-specific factors, biomarker status, and sequencing implications

Target Audience:

This educational activity is directed toward oncologists, NPs/PAs, nurses, pharmacists, and other HCPs involved in the management of lung cancer.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.